Stewart Tepper

AHS highlights: atogepant and zavegepant for migraine treatment 2:05
AHS highlights: atogepant and zavegepant for migraine treatment
Stewart Tepper • 17 Jun 2022
Assessing the efficacy of fremanezumab on interictal migraine related burden 4:17
Assessing the efficacy of fremanezumab on interictal migraine related burden
Stewart Tepper • 17 Jun 2022
Discontinuation of anti-CGRP antibodies in non-responders 2:00
Discontinuation of anti-CGRP antibodies in non-responders
Stewart Tepper • 17 Jun 2022
Increased placebo response over time in migraine preventive trials 5:55
Increased placebo response over time in migraine preventive trials
Stewart Tepper • 17 Jun 2022
Therapeutic landscape for cluster headache 11:31
Therapeutic landscape for cluster headache
Stewart Tepper • 24 May 2020
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic 20:54
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic
Stewart Tepper • 24 May 2020
Benefit of migraine prevention with erenumab 19:11
Benefit of migraine prevention with erenumab
Stewart Tepper • 24 May 2020
CONQUER: galcanezumab in treatment-resistant migraine 9:29
CONQUER: galcanezumab in treatment-resistant migraine
Stewart Tepper • 24 May 2020
Erenumab in migraine with or without aura: cardiovascular safety 7:37
Erenumab in migraine with or without aura: cardiovascular safety
Stewart Tepper • 24 May 2020
The content of VJNeurology is intended for healthcare professionals